[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608347":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":197,"collaborators":10,"id":199,"slug":200,"hasResults":201,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":201,"sex":207,"minAge":208,"maxAge":10,"enrollmentInfo":209,"targetDuration":10,"studyType":212,"phases":10,"briefSummary":213,"conditions":214,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":225},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Glofitamab treatment",null,"Participants will be enrolled into the study either prior to initiation of glofitamab therapy or within 90 days of starting glofitamab therapy.",[13],"Drug: Glofitamab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Glofitamab","Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.",[9],[21],{"name":22,"affiliation":5,"role":23},"Clinical Trials","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Reference Study ID Number: ML45172 https:\u002F\u002Fforpatients.roche.com\u002F No attachments to email below.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":10},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[33,47,57,66,72,80,89,98,107,116,125,131,137,146,155,161,170,179,188],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":10},"Cancer Hospital Chinese Academy of Medical Sciences.","RECRUITING","Langfang","Hebei","065001","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.71471,39.52079,{"lat":45,"lon":44},{"facility":48,"status":35,"city":49,"state":50,"zip":51,"country":39,"countryCode":40,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center","Tianjin","Tianjin Municipality","301636",{"type":42,"coordinates":53},[54,55],117.17667,39.14222,{"lat":55,"lon":54},{"facility":58,"status":35,"city":59,"state":10,"zip":60,"country":39,"countryCode":40,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"Peking University People's Hospital","Beijing","100044",{"type":42,"coordinates":62},[63,64],116.39723,39.9075,{"lat":64,"lon":63},{"facility":67,"status":35,"city":59,"state":10,"zip":68,"country":39,"countryCode":40,"cosmosGeoPoint":69,"geoPoint":71,"contacts":10},"Peking University Third Hospital","100191",{"type":42,"coordinates":70},[63,64],{"lat":64,"lon":63},{"facility":73,"status":35,"city":74,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":75,"geoPoint":79,"contacts":10},"The First Bethune Hospital of Jilin University","Changchun",{"type":42,"coordinates":76},[77,78],125.32278,43.88,{"lat":78,"lon":77},{"facility":81,"status":35,"city":82,"state":10,"zip":83,"country":39,"countryCode":40,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"West China Hospital of Sichuan University","Chengdu","610041",{"type":42,"coordinates":85},[86,87],104.06667,30.66667,{"lat":87,"lon":86},{"facility":90,"status":35,"city":91,"state":10,"zip":92,"country":39,"countryCode":40,"cosmosGeoPoint":93,"geoPoint":97,"contacts":10},"Guangdong Provincial People's Hospital","Guangzhou","510080",{"type":42,"coordinates":94},[95,96],113.25,23.11667,{"lat":96,"lon":95},{"facility":99,"status":35,"city":100,"state":10,"zip":101,"country":39,"countryCode":40,"cosmosGeoPoint":102,"geoPoint":106,"contacts":10},"Harbin Medical University Cancer Hospital","Harbin","150081",{"type":42,"coordinates":103},[104,105],126.65,45.75,{"lat":105,"lon":104},{"facility":108,"status":35,"city":109,"state":10,"zip":110,"country":39,"countryCode":40,"cosmosGeoPoint":111,"geoPoint":115,"contacts":10},"Shandong Cancer Hospital","Jinan","250117",{"type":42,"coordinates":112},[113,114],116.99722,36.66833,{"lat":114,"lon":113},{"facility":117,"status":35,"city":118,"state":10,"zip":119,"country":39,"countryCode":40,"cosmosGeoPoint":120,"geoPoint":124,"contacts":10},"Ruijin Hospital, Shanghai Jiaotong University School of Medicine","Shanghai","200025",{"type":42,"coordinates":121},[122,123],121.45806,31.22222,{"lat":123,"lon":122},{"facility":126,"status":35,"city":118,"state":10,"zip":127,"country":39,"countryCode":40,"cosmosGeoPoint":128,"geoPoint":130,"contacts":10},"Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","200233",{"type":42,"coordinates":129},[122,123],{"lat":123,"lon":122},{"facility":132,"status":35,"city":49,"state":10,"zip":133,"country":39,"countryCode":40,"cosmosGeoPoint":134,"geoPoint":136,"contacts":10},"Tianjin Cancer Hospital","300060",{"type":42,"coordinates":135},[54,55],{"lat":55,"lon":54},{"facility":138,"status":35,"city":139,"state":10,"zip":140,"country":39,"countryCode":40,"cosmosGeoPoint":141,"geoPoint":145,"contacts":10},"The First Affiliated Hospital of Wenzhou Medical University","Wenzhou","325035",{"type":42,"coordinates":142},[143,144],120.66682,27.99942,{"lat":144,"lon":143},{"facility":147,"status":35,"city":148,"state":10,"zip":149,"country":39,"countryCode":40,"cosmosGeoPoint":150,"geoPoint":154,"contacts":10},"Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology","Wuhan","430022",{"type":42,"coordinates":151},[152,153],114.26667,30.58333,{"lat":153,"lon":152},{"facility":156,"status":35,"city":148,"state":10,"zip":157,"country":39,"countryCode":40,"cosmosGeoPoint":158,"geoPoint":160,"contacts":10},"Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology","430030",{"type":42,"coordinates":159},[152,153],{"lat":153,"lon":152},{"facility":162,"status":35,"city":163,"state":10,"zip":164,"country":39,"countryCode":40,"cosmosGeoPoint":165,"geoPoint":169,"contacts":10},"The First Affiliated Hospital of Xian Jiao Tong University","Xi'an","710061",{"type":42,"coordinates":166},[167,168],108.92861,34.25833,{"lat":168,"lon":167},{"facility":171,"status":35,"city":172,"state":10,"zip":173,"country":39,"countryCode":40,"cosmosGeoPoint":174,"geoPoint":178,"contacts":10},"Yantai Yu Huangding Hospital","Yantai","264099",{"type":42,"coordinates":175},[176,177],121.44081,37.47649,{"lat":177,"lon":176},{"facility":180,"status":35,"city":181,"state":10,"zip":182,"country":39,"countryCode":40,"cosmosGeoPoint":183,"geoPoint":187,"contacts":10},"Henan Cancer Hospital","Zhengzhou","450008",{"type":42,"coordinates":184},[185,186],113.64861,34.75778,{"lat":186,"lon":185},{"facility":189,"status":35,"city":190,"state":10,"zip":10,"country":190,"countryCode":191,"cosmosGeoPoint":192,"geoPoint":196,"contacts":10},"Queen Mary Hospital","Hong Kong","HK",{"type":42,"coordinates":193},[194,195],114.17469,22.27832,{"lat":195,"lon":194},{"type":198,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100608347","an-observational-study-of-glofitamab-in-chinese-adult-participants-with-2l-diffuse-large-b-cell-lymphoma-100608347",false,"NCT07200375","An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma","Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study","GlofitReal","Inclusion Criteria:\n\n* Histologically confirmed R\u002FR DLBCL after one line of systemic therapy\n* Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment\n\nExclusion Criteria:\n\n* Participants who currently participate in or plan to participate in any interventional clinical trial","ALL","18 Years",{"count":210,"type":211},300,"ESTIMATED","OBSERVATIONAL","This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R\u002FR DLBCL).",[215],"Diffuse Large B-Cell Lymphoma","2026-07-01",{"date":218,"type":219},"2026-07-02","ACTUAL",{"date":221,"type":219},"2025-09-29",{"date":223,"type":211},"2029-09-29",{"name":5,"class":6},19]